DK3511330T3 - Syntetisk mellemprodukt, der er anvendeligt til fremstilling af triazolopyridin-c-met-inhibitorer - Google Patents

Syntetisk mellemprodukt, der er anvendeligt til fremstilling af triazolopyridin-c-met-inhibitorer Download PDF

Info

Publication number
DK3511330T3
DK3511330T3 DK19151824.0T DK19151824T DK3511330T3 DK 3511330 T3 DK3511330 T3 DK 3511330T3 DK 19151824 T DK19151824 T DK 19151824T DK 3511330 T3 DK3511330 T3 DK 3511330T3
Authority
DK
Denmark
Prior art keywords
triazolopyridine
manufacture
synthetic intermediate
met inhibitors
intermediate use
Prior art date
Application number
DK19151824.0T
Other languages
English (en)
Inventor
Wei-Guo Su
Hong Jia
Guangxiu Dai
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3511330(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Application granted granted Critical
Publication of DK3511330T3 publication Critical patent/DK3511330T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
DK19151824.0T 2009-12-31 2010-12-30 Syntetisk mellemprodukt, der er anvendeligt til fremstilling af triazolopyridin-c-met-inhibitorer DK3511330T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31
EP15170608.2A EP2966075B1 (en) 2009-12-31 2010-12-30 Certain triazolopyridines, compositions thereof and their use in the treatment of cancer.

Publications (1)

Publication Number Publication Date
DK3511330T3 true DK3511330T3 (da) 2020-12-21

Family

ID=44226181

Family Applications (3)

Application Number Title Priority Date Filing Date
DK20199091.8T DK3795573T3 (da) 2009-12-31 2010-12-30 Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK13198224.1T DK2719699T3 (da) 2009-12-31 2010-12-30 Bestemte triazolopyraziner, præparater dermed og fremgangsmåder til anvendelse deraf
DK19151824.0T DK3511330T3 (da) 2009-12-31 2010-12-30 Syntetisk mellemprodukt, der er anvendeligt til fremstilling af triazolopyridin-c-met-inhibitorer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK20199091.8T DK3795573T3 (da) 2009-12-31 2010-12-30 Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK13198224.1T DK2719699T3 (da) 2009-12-31 2010-12-30 Bestemte triazolopyraziner, præparater dermed og fremgangsmåder til anvendelse deraf

Country Status (38)

Country Link
US (9) US8987269B2 (da)
EP (5) EP2719699B1 (da)
JP (5) JP5337313B2 (da)
KR (3) KR101905350B1 (da)
CN (3) CN106432225B (da)
AU (2) AU2010338712B2 (da)
BR (1) BR112012016129B1 (da)
CA (1) CA2785749C (da)
CL (1) CL2012001752A1 (da)
CO (1) CO6612235A2 (da)
CU (1) CU24167B1 (da)
CY (3) CY1118250T1 (da)
DK (3) DK3795573T3 (da)
DO (1) DOP2012000188A (da)
EA (2) EA030141B1 (da)
EC (1) ECSP12012011A (da)
ES (4) ES2726152T3 (da)
GT (1) GT201200220A (da)
HR (3) HRP20221090T1 (da)
HU (3) HUE052828T2 (da)
IL (2) IL220433B (da)
LT (1) LT3795573T (da)
ME (1) ME02211B (da)
MX (2) MX386852B (da)
MY (1) MY179933A (da)
NI (1) NI201200118A (da)
NZ (1) NZ601128A (da)
PE (3) PE20130375A1 (da)
PH (1) PH12012501355A1 (da)
PL (3) PL3795573T3 (da)
PT (3) PT2719699E (da)
RS (3) RS61281B1 (da)
SG (1) SG181781A1 (da)
SI (2) SI2719699T1 (da)
SM (3) SMT202000693T1 (da)
UA (1) UA107822C2 (da)
WO (1) WO2011079804A1 (da)
ZA (1) ZA201205730B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61281B1 (sr) * 2009-12-31 2021-02-26 Hutchison Medipharma Ltd Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
EP3450432A1 (en) * 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
AP3908A (en) * 2012-03-30 2016-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
CA2776178A1 (en) 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
WO2014109414A1 (ja) * 2013-01-11 2014-07-17 富士フイルム株式会社 含窒素複素環化合物またはその塩
MX362247B (es) 2013-03-06 2019-01-09 Astrazeneca Ab Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico.
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
AU2013402175B2 (en) * 2013-09-30 2017-09-07 Handok Inc. Novel triazolopyrazine derivative and use thereof
CA2934667A1 (en) * 2013-12-26 2015-07-02 Ignyta, Inc. Pyrazolo[1,5-a]pyridine derivatives and methods of their use
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
CN106928232B (zh) * 2015-12-31 2019-07-09 上海医药集团股份有限公司 喹啉类化合物及其盐的晶型、制备方法、组合物与应用
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
KR102632860B1 (ko) 2017-03-01 2024-02-02 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
IL281283B2 (en) * 2018-09-11 2024-01-01 Astrazeneca Ab Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
EP3856164B1 (en) 2018-09-25 2024-08-07 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
JP2022510501A (ja) * 2018-10-30 2022-01-26 リペア セラピューティクス インコーポレイテッド 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法
US12258365B2 (en) 2018-12-14 2025-03-25 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof
BR112021011727A2 (pt) 2018-12-17 2021-08-31 Achillion Pharmaceuticals, Inc Dosagem direcionada para o tratamento de distúrbios mediados do complemento
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
AU2020317381A1 (en) * 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
CN115362162A (zh) * 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
WO2022066534A1 (en) * 2020-09-28 2022-03-31 Codexis, Inc. Engineered biocatalysts and methods for synthesizing chiral amines
EP4263523A2 (en) * 2020-12-16 2023-10-25 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
KR102659095B1 (ko) 2021-01-08 2024-04-19 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
CN117897384A (zh) 2021-06-28 2024-04-16 缆图药品公司 Cdk2抑制剂
JP2025513560A (ja) * 2022-04-20 2025-04-24 エングレイル セラピューティクス，インコーポレーテッド Ｇａｂａａ受容体モジュレーター塩、粒子、およびその使用
EP4551226A1 (en) 2022-07-08 2025-05-14 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
CN119998281A (zh) * 2022-07-29 2025-05-13 贝勒医学院 神经营养受体酪氨酸激酶(ntrk)抑制剂及其使用方法
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法
CN120835885A (zh) * 2023-01-04 2025-10-24 缆图药品公司 Cdk2抑制剂
GB202300923D0 (en) * 2023-01-20 2023-03-08 Macfarlan Smith Ltd Novel polymorphic forms of savolitinib
WO2024263860A1 (en) * 2023-06-22 2024-12-26 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2333040A1 (en) * 1998-05-26 1999-12-02 Merck & Co., Inc. Imidazopyridine thrombin inhibitors
JP2000119250A (ja) * 1998-08-11 2000-04-25 Takeda Chem Ind Ltd 環状アミド化合物、その製造法、中間体及び除草剤
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
JP2007516180A (ja) * 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
EP2264033A1 (en) 2004-07-27 2010-12-22 SGX Pharmaceuticals, Inc. 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS
JP2008509987A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー トリアゾロピリジン化合物
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
WO2006087538A1 (en) * 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
HUE030390T2 (en) 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
EP2032578A2 (en) 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
WO2008036272A1 (en) 2006-09-18 2008-03-27 Vertex Pharmaceuticals Incorporated HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF
CA2667428A1 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
KR101083177B1 (ko) * 2006-10-23 2011-11-11 에스지엑스 파마슈티컬스, 인코포레이티드 트리아졸로-피리다진 단백질 키나제 조정제
ES2560435T3 (es) 2006-11-22 2016-02-19 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CN101679436A (zh) 2007-04-10 2010-03-24 Sgx药品公司 稠环杂环激酶调节剂
WO2008138842A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
EP2285216A4 (en) * 2008-02-21 2012-09-19 Sequoia Pharmaceuticals Inc HIV PROTEASE INHIBITOR AND COMBINED CYTOCHROME P450 INHIBITOR
PE20091468A1 (es) 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
US8691838B2 (en) 2008-05-22 2014-04-08 Amgen Inc. Heterocycles as protein kinase inhibitors
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EA201200260A1 (ru) * 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002179A (es) * 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
RS61281B1 (sr) * 2009-12-31 2021-02-26 Hutchison Medipharma Ltd Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
EP3450432A1 (en) 2010-05-17 2019-03-06 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases

Also Published As

Publication number Publication date
AU2010338712B2 (en) 2015-04-02
SG181781A1 (en) 2012-07-30
ES2546635T3 (es) 2015-09-25
AU2015203480B2 (en) 2017-10-26
US8507487B2 (en) 2013-08-13
ME02211B (me) 2016-02-20
JP2018009004A (ja) 2018-01-18
PE20130375A1 (es) 2013-04-10
SI3511330T1 (sl) 2021-01-29
US20180263977A1 (en) 2018-09-20
UA107822C2 (xx) 2015-02-25
JP2016155848A (ja) 2016-09-01
SI2719699T1 (sl) 2015-12-31
EA201200951A1 (ru) 2013-09-30
EP3511330A1 (en) 2019-07-17
RS54217B1 (sr) 2015-12-31
MX2012007756A (es) 2012-11-06
EP2519524A1 (en) 2012-11-07
EP2966075A1 (en) 2016-01-13
JP6486999B2 (ja) 2019-03-20
RS61281B1 (sr) 2021-02-26
EP2966075B1 (en) 2019-02-27
CU24167B1 (es) 2016-03-31
HUE052828T2 (hu) 2021-05-28
HRP20221090T1 (hr) 2022-11-25
AU2010338712A1 (en) 2012-07-12
JP5337313B2 (ja) 2013-11-06
ES2726152T3 (es) 2019-10-02
EA030141B1 (ru) 2018-06-29
AU2015203480A1 (en) 2015-07-16
KR20170098324A (ko) 2017-08-29
KR101434766B1 (ko) 2014-08-26
US20240139182A1 (en) 2024-05-02
EA201691461A1 (ru) 2017-01-30
CY1118250T1 (el) 2017-06-28
EP2719699A1 (en) 2014-04-16
CN106117248B (zh) 2019-01-22
US20150368271A1 (en) 2015-12-24
PE20160588A1 (es) 2016-07-09
EP2519524A4 (en) 2013-07-03
US20210154192A1 (en) 2021-05-27
PL2719699T3 (pl) 2016-01-29
IL239997A (en) 2017-11-30
CY1123777T1 (el) 2022-03-24
ECSP12012011A (es) 2012-10-30
JP2013516393A (ja) 2013-05-13
PH12012501355A1 (en) 2012-12-17
IL239997A0 (en) 2015-08-31
GT201200220A (es) 2014-12-22
KR20120125261A (ko) 2012-11-14
CN106432225A (zh) 2017-02-22
CU20120101A7 (es) 2012-10-15
CA2785749A1 (en) 2011-07-07
KR20140059307A (ko) 2014-05-15
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
SMT202200371T1 (it) 2022-11-18
WO2011079804A1 (en) 2011-07-07
PL3795573T3 (pl) 2022-11-21
HRP20150952T1 (hr) 2015-10-09
MY179933A (en) 2020-11-19
ES2927146T3 (es) 2022-11-02
JP2019108345A (ja) 2019-07-04
CO6612235A2 (es) 2013-02-01
ZA201205730B (en) 2016-01-27
IL220433B (en) 2018-01-31
CL2012001752A1 (es) 2013-01-25
EP2719699B1 (en) 2015-07-08
SMT201500213B (it) 2015-10-30
DOP2012000188A (es) 2012-12-31
DK3795573T3 (da) 2022-09-19
US8987269B2 (en) 2015-03-24
US20120245178A1 (en) 2012-09-27
CN102906092B (zh) 2016-08-03
DK2719699T3 (da) 2015-08-24
US10512645B2 (en) 2019-12-24
PT3511330T (pt) 2020-12-24
EP3511330B1 (en) 2020-09-30
MX336996B (es) 2016-02-09
JP6647434B2 (ja) 2020-02-14
CY1125550T1 (el) 2026-02-25
RS63612B1 (sr) 2022-10-31
US20170027934A1 (en) 2017-02-02
KR101905350B1 (ko) 2018-11-30
JP6194046B2 (ja) 2017-09-06
HUE059696T2 (hu) 2022-12-28
EA025466B1 (ru) 2016-12-30
US11896592B2 (en) 2024-02-13
PL3511330T3 (pl) 2021-04-19
CN106117248A (zh) 2016-11-16
US20120264739A1 (en) 2012-10-18
US20250099462A1 (en) 2025-03-27
MX386852B (es) 2025-03-19
NZ601128A (en) 2014-12-24
HK1194071A1 (en) 2014-10-10
HK1216880A1 (en) 2016-12-09
CN102906092A (zh) 2013-01-30
US9956218B2 (en) 2018-05-01
JP2013209418A (ja) 2013-10-10
CN106432225B (zh) 2019-02-19
ES2840454T3 (es) 2021-07-06
PT2719699E (pt) 2015-09-30
EP3795573A1 (en) 2021-03-24
HRP20202017T1 (hr) 2021-02-19
EP3795573B1 (en) 2022-07-06
US10946014B2 (en) 2021-03-16
BR112012016129B1 (pt) 2020-11-03
CA2785749C (en) 2017-11-28
SMT202000693T1 (it) 2021-01-05
KR101771299B1 (ko) 2017-08-24
HUE025504T2 (en) 2016-02-29
US20200179377A1 (en) 2020-06-11
LT3795573T (lt) 2022-11-10
PT3795573T (pt) 2022-09-15
BR112012016129A2 (pt) 2016-05-31

Similar Documents

Publication Publication Date Title
LTPA2020505I1 (lt) Nauji tricikliniai junginiai
DK2310382T3 (da) Amidophenoxyindazoler, der er anvendelige som hæmmere af c-met
DK2376490T3 (da) Imidazopyridinforbindelser
BRPI0915374A2 (pt) Novos compostos tricíclicos
BRPI0914657A2 (pt) piridin-2-onae piridazin-3-onas substituídas
DK3495367T3 (da) Substituerede tricykliske forbindelser som fgfr-inhibitorer
DK2691079T3 (da) Bionedbrydelige sammensætninger, der er egnet til kontrolleret udløsning
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
DK2470546T3 (da) HEXAHYDROOXAZINOPTERIDIN- forbindelser til anvendelse som mTOR INHIBITORER
DK2427449T3 (da) Vinylindazolylforbindelser
DK2648516T3 (da) Substituerede pyridinon-pyridinylforbindelser
BR112012006859A2 (pt) compostos
EP2752602A4 (en) sliding component
DK2571963T3 (da) Sammensætninger, der tilvejebringer renseegenskab
DK2571903T3 (da) Polymerer, der reagerer på stimuli, til oprensning af biomolekyler
DK2595948T3 (da) Fremgangsmåde til fremstilling af ingenol-3-angelat
DK2401256T3 (da) Forbindelser som bradykinin-B1-antagonister.
IL225969A0 (en) Triazolopyridine compounds
UY33156A (es) Nuevos compuestos tienopirrol
EP2703667A4 (en) SLIDING MENT
IL225895A0 (en) Anti-diabetic compounds
DK2618842T3 (da) Hidtil ukendt immunstimulerende fremgangsmåde
EP2519519A4 (en) Substituted Naphthalenyl-pyrimidine compounds
DK2342182T3 (da) Isoquinolinonderivater som nk3-antagonister
DK2516359T3 (da) Fremgangsmåde til fremstilling af ethylbenzen